PathWhiz

PathWhiz ID	Pathway	Meta Data
PW128242 View Pathway	drug action Tenecteplase Action Pathway (new) Homo sapiens Tenecteplase is a plasminogen activator, a modified form of recombinant human tissue, also known as Metalyse and Tnkase, used in emergencies such as myocardial infarction and pulmonary emboli. It is administered intravenously and travels through the bloodstream to target blood clots by activating plasminogen. Tenecteplase acts on plasminogen by cleaving an arginine-valine bond and converting it to its active form of plasmin. Plasmin then acts on the blood clot fibrin mesh and degrades it into degradation products eliminating the blood clot. Due to its anticoagulant and antiplatelet activity herbs and supplements with similar activity should be avoided such as garlic, ginger, bilberry, danshen, piracetam and ginkgo biloba. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Selena Created On: August 08, 2023 at 15:24 Last Updated: August 08, 2023 at 15:24
PW124151 View Pathway	drug action Teniposide Action Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Aadhavya Sivakumaran Created On: September 09, 2020 at 22:06 Last Updated: September 09, 2020 at 22:06
PW000246 View Pathway	drug action Teniposide Action Pathway Homo sapiens Teniposide is a type of chemotherapy drug, derived from the epipodophyllotoxin form the American Mayapple plant. Teniposide is related to etoposide, another anti-cancer drug. It works in a similar way, inhibiting topoisomerase II. This causes single- and double-stranded DNA breaks. These breaks cause cell growth to stop and prevents cancer cells from entering mitosis. It is administered through an intravenous infusion. It is used to treat many cancers such as lymphoma, leukemia (acute lymphocytic), and neuroblastoma. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: WishartLab Created On: August 22, 2013 at 10:45 Last Updated: August 22, 2013 at 10:45
PW144569 View Pathway	drug action Teniposide Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 13:55 Last Updated: October 07, 2023 at 13:55
PW000578 View Pathway	drug metabolism Teniposide Metabolism Pathway Homo sapiens Teniposide is a type of chemotherapy drug, derived from the epipodophyllotoxin form the American Mayapple plant. Teniposide is related to etoposide, another anti-cancer drug. It works in a similar way, inhibiting topoisomerase II. This causes single- and double-stranded DNA breaks. These breaks cause cell growth to stop and prevents cancer cells from entering mitosis. It is administered through an intravenous infusion. It is used to treat many cancers such as lymphoma, leukemia (acute lymphocytic), and neuroblastoma. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: WishartLab Created On: September 11, 2013 at 22:32 Last Updated: September 11, 2013 at 22:32
PW176234 View Pathway	metabolic Teniposide Predicted Metabolism Pathway Homo sapiens Metabolites of Teniposide are predicted with biotransformer. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: December 04, 2023 at 13:02 Last Updated: December 04, 2023 at 13:02
PW000437 View Pathway	drug action Tenofovir Action Pathway Homo sapiens Tenofovir is a nucleotide analogue used in the treatment of HIV and chronic hepatitis B. It is taken up into the cell and is subsequently phosphorylated first by adenylate kinases and then by nucleoside diphosphate kinases into tenofovir diphosphate. Tenofovir diphosphate is an analogue of deoxyadenosine triphosphate (dATP) and competes with dATP for binding to the viral DNA polymerase and subsequent incorporation into the growing DNA strand. Once incorporated into the DNA, tenofovir causes chain termination, thus preventing viral replication. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: WishartLab Created On: August 22, 2013 at 10:46 Last Updated: August 22, 2013 at 10:46
PW126444 View Pathway	drug action Tenofovir Action Pathway (New) Homo sapiens Tenofovir is a nucleotide analog that has shown to be effective against HIV, herpes simplex virus-2, and hepatitis B virus. When HIV infects a cell, the virus first binds and fuses with the cell, releasing its nucleocapsid containing its RNA and reverse transcriptase into the cytosol of the cell. The reverse transcriptase converts the viral RNA into viral DNA in the cytosol. The viral DNA goes to the nucleus through the nuclear pore complex where it undergoes the process of transcription. The new viral RNA formed from transcription is transported back to the cytosol through the nuclear pore complex and translation occurs to produce viral proteins. These viral proteins are assembled and new HIV viruses bud from the cell. Tenofovir enters the cell via solute carrier family 22 member 8 and is converted into tenofovir monophosphate by adenylate kinase. Nucleoside diphosphate kinase then converts tenofovir monophosphate into tenofovir diphosphate. Tenofovir diphosphate is an analog of deoxyadenosine triphosphate (dATP). Tenofovir diphosphate inhibits the activity of HIV-1 reverse transcriptase by competing with its substrate, dATP and by incorporation into viral DNA. Tenofovir diphosphate lacks the 3'-OH group which is needed to form the 5′ to 3′ phosphodiester linkage essential for DNA chain elongation, therefore, once tenofovir diphosphate gets incorporated into DNA, this causes DNA chain termination, preventing the growth of viral DNA. Less viral proteins are therefore produced, and there is a reduction in new viruses being formed. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Karxena Harford Created On: December 05, 2021 at 22:06 Last Updated: December 05, 2021 at 22:06
PW127479 View Pathway	drug action Tenofovir Alafenamide Action Pathway Homo sapiens Tenofovir alafenamide is a novel tenofovir prodrug nucleoside analog reverse transcriptase inhibitor developed in order to improve renal safety when compared to the counterpart tenofovir disoproxil. It is used for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease. Both of these prodrugs were first created to cover the polar phosphonic acid group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and intestinal diffusion. In the liver, tenofovir alafenamide is converted into tenofovir alanine by the enzymes Lysosomal protective protein and Liver carboxylesterase 1.Tenofovir alanine is then converted to Tenofovir by the enzyme Histidine triad nucleotide-binding protein 1. It is then transported into the blood via multidrug resistance-associated protein 4 or Solute carrier family 22 then into the infected cell via the same or similar transporters. Tenofovir is then converted to the active metabolite, tenofovir diphosphate, a chain terminator, by constitutively expressed enzymes in the cell. Tenofovir diphosphate inhibits HIV-1 reverse transcriptase and the Hepatitis B polymerase by direct binding in competition with dATP. After integration into DNA, causes viral DNA chain termination. Tenofovir diphosphate lacks the 3'-OH group which is needed to form the 5′ to 3′ phosphodiester linkage essential for DNA chain elongation, therefore, once tenofovir diphosphate gets incorporated into DNA, this causes DNA chain termination, preventing the growth of viral DNA. Less viral proteins are therefore produced, and there is a reduction in new viruses being formed. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: March 09, 2023 at 15:38 Last Updated: March 09, 2023 at 15:38
PW146077 View Pathway	drug action Tenofovir alafenamide Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 17:21 Last Updated: October 07, 2023 at 17:21